IPP Bureau
Lupin receives EIR from FDA for its Aurangabad facility
By IPP Bureau - November 13, 2025
The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million
By IPP Bureau - November 13, 2025
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
Zydus receives China's NMPA approval for Venlafaxine ER capsules, 75 mg and 150 mg
By IPP Bureau - November 13, 2025
Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag
By IPP Bureau - November 13, 2025
Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities
By IPP Bureau - November 13, 2025
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Philogen updates on Fibromun clinical study developments
By IPP Bureau - November 13, 2025
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components
By IPP Bureau - November 13, 2025
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”
By IPP Bureau - November 12, 2025
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
Novartis opens radioligand therapy manufacturing facility in California
By IPP Bureau - November 12, 2025
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Tata 1mg boosts delivery speed with AI-driven logistics
By IPP Bureau - November 12, 2025
This partnership has led to a 10% boost in delivery speed
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
By IPP Bureau - November 12, 2025
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Moraine appointed as distributor for OTSAW’s Hospital robots in Japan
By IPP Bureau - November 12, 2025
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
By IPP Bureau - November 12, 2025
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
By IPP Bureau - November 12, 2025
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
Shilpa Medicare announces positive Phase 3 results for Oeris
By IPP Bureau - November 12, 2025
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
